Skip to content

Outlook Therapeutics

3 viewers · 30d

Total raised

—

2 filings since 2025 · no dollar figures disclosed

No disclosed amounts to chart
LAST ROUND
Equity
ROUNDS
2
INVESTORS
10
FOUNDED
N/A
HQ
Iselin, NJ
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Outlook Therapeutics is a pioneering biopharmaceutical company specializing in the development and commercialization of ophthalmic medications. The company is committed to addressing significant unmet medical needs in the treatment of retinal diseases through innovative therapeutic solutions.

What sets it apart

Outlook Therapeutics distinguishes itself by developing the first FDA-approved ophthalmic formulation of bevacizumab, directly addressing a current gap in the treatment of retinal diseases like wet AMD.

Funding history

2 rounds
Equity+2Apr 23, 2026
Form D
—— total
Equity+2Jan 17, 2025
Form D
—— total

Products

1 tracked

ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Retinal Disease Treatment

This product is an innovative ophthalmic formulation of bevacizumab specifically designed to meet FDA standards. It is intended for the treatment of various retinal diseases, particularly wet age-related macular degeneration.

  • FDA approval-seeking formulation
  • Reduces reliance on off-label drug use
  • Targeted treatment for multiple retinal conditions

Links

WebsiteSEC EDGAR filings